Remove Heart Transplant Remove Quality of Life Remove Technology
article thumbnail

Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy

Frontiers in Cardiovascular Medicine

At present, the main methods to treat ischemic heart disease are drug therapy, intervention and operation. These methods only alleviate symptoms of heart failure and myocardial ischemia and improve patients' quality of life by partially restoring myocardial reperfusion.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

Dr. William Abraham of the Ohio State Wexner College of Medicine presented analysis showing that patients in the trial with Barostim + GDMT had a 74% reduced risk of receiving advanced heart failure interventions (transplant, LVAD, CCM, CRT or CardioMEMS) at long-term follow-up versus patients on GDMT alone. See more details at TCTMD.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Treated patients also had reduced major adverse cardiac events and greatly improved quality of life. “We said Peter Altman , PhD.,

CMS 111
article thumbnail

What is new in Heart failure management ? Ultrasonic cardiac re-synchronization : The WiSE -CRT device

Dr. S. Venkatesan MD

We now have one more technology, on the verge of approval by the FDA. Final message WiSE CRT uses some revolutionary technology and it is a welcome addition in few eligible patients. However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. 2021 May 21;23(5):740-747.

article thumbnail

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

DAIC

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave. healthcare system.

article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)